Investigational Drug Information for Chiglitazar
✉ Email this page to a colleague
What is the development status for investigational drug Chiglitazar?
Chiglitazar is an investigational drug.
There have been 8 clinical trials for Chiglitazar.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Affiliated Hospital of Nantong University, and [disabled in preview].
There are sixty-six US patents protecting this investigational drug and five hundred and ninety-nine international patents.
Summary for Chiglitazar
US Patents | 66 |
International Patents | 599 |
US Patent Applications | 129 |
WIPO Patent Applications | 134 |
Japanese Patent Applications | 46 |
Clinical Trial Progress | Phase 3 (2014-06-01) |
Vendors | 23 |
Recent Clinical Trials for Chiglitazar
Title | Sponsor | Phase |
---|---|---|
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects. | Chipscreen Biosciences, Ltd. | Phase 1 |
Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM | Affiliated Hospital of Nantong University | Phase 1 |
Pharmacokinetics of Chiglitazar in Subjects With Hepatic Impairment and Normal Hepatic Function | Chipscreen Biosciences, Ltd. | Phase 1 |
Clinical Trial Summary for Chiglitazar
Top disease conditions for Chiglitazar
Top clinical trial sponsors for Chiglitazar
US Patents for Chiglitazar
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
Chiglitazar | ⤷ Try a Trial | Fused heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Try a Trial |
Chiglitazar | ⤷ Try a Trial | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Tokyo, JP) | ⤷ Try a Trial |
Chiglitazar | ⤷ Try a Trial | Soluble guanylate cyclase stimulators | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
Chiglitazar | ⤷ Try a Trial | Antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
Chiglitazar | ⤷ Try a Trial | Peptide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (Osaka, JP) | ⤷ Try a Trial |
Chiglitazar | ⤷ Try a Trial | [5,6]--fused bicyclic antidiabetic compounds | Merck Sharp & Dohme Corp. (Rahway, NJ) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Chiglitazar
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
Chiglitazar | European Patent Office | EP3275874 | 2035-03-27 | ⤷ Try a Trial |
Chiglitazar | Japan | JP6634070 | 2035-03-27 | ⤷ Try a Trial |
Chiglitazar | Japan | JPWO2016158788 | 2035-03-27 | ⤷ Try a Trial |
Chiglitazar | World Intellectual Property Organization (WIPO) | WO2016158788 | 2035-03-27 | ⤷ Try a Trial |
Chiglitazar | Argentina | AR099399 | 2034-02-13 | ⤷ Try a Trial |
Chiglitazar | Australia | AU2015216439 | 2034-02-13 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |